About this trial
FAP-targeted PET imaging using 68Ga-FAPI enables early detection of myocardial fibrosis. Combined PET/CMR provides comprehensive cardiac assessment without extra radiation. This advanced imaging approach improves diagnosis and personalized treatment for better patient outcomes.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Participants must have a confirmed clinical diagnosis of cardiovascular disease by a cardiologist, based on genetic testing, family history, and comprehensive clinical evaluation including physical examination, echocardiography, and when indicated, cardiac MRI findings.
Age requirement: >18 years.
Patients should demonstrate stable cardiovascular status without significant changes in symptoms, treatment, or clinical findings for a specified pre-enrollment period.
Participants must be capable of providing informed consent and willing to adhere to all study requirements, including follow-up procedures.
Disqualifiers
History of malignancy
Documented cardiovascular diseases, including coronary artery disease, myocardial infarction, or related conditions
Implanted metallic devices (e.g., pacemakers, aneurysm clips) or other MRI-incompatible medical prostheses
Claustrophobia
Trial population
Patients with cardiovascular diseases
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
CE-CMR
Left ventricular wall thickness was quantified on short-axis cine images using the MR cardiac analysis software .
CE-MRI
Left ventricular ejection fraction (LVEF) was calculated from short-axis cine images using the cardiac MR analysis software.
PET
The maximum standardized uptake value (SUVmax) was calculated for each myocardial segment.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.